Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 12/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289362 | 0.88 | AR (0.55) | ARSLC22A12TAS2R14ABCG2PGR | |
| SCHEMBL4903311 | 0.85 | AR (0.52) | ARSLC22A12TAS2R14ABCG2PGR | |
| SCHEMBL4898542 | 0.82 | AR (0.50) | ARSLC22A12TAS2R14 | |
| SCHEMBL4898546 | 0.82 | AR (0.50) | ARSLC22A12TAS2R14 | |
| SCHEMBL19976340 | 0.82 | AR (0.50) | ARSLC22A12TAS2R14PGR | |
| SCHEMBL4905143 | 0.82 | AR (0.50) | ARSLC22A12TAS2R14 | |
| SCHEMBL3289355 | 0.81 | AR (0.47) | ARSLC22A12TAS2R14 | |
| SCHEMBL5120802 | 0.81 | AR (0.49) | ARSLC22A12TAS2R14PGR | |
| SCHEMBL24632242 | 0.81 | AR (0.49) | ARSLC22A12TAS2R14 | |
| SCHEMBL3044589 | 0.80 | AR (0.48) | ARSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-1725522-B1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723385-B2 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-25 | — | — | US | disclosed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514470-B2 | Aniline derivatives as selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | GLAXOSMITHKLINE LLC | 2007-08-16 | — | — | US | disclosed |
| EP-1725522-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085185-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163588-A1 | ANILINE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, NR3C2, NR5A1 | AR 1/4885SLC22A12 2416/4885TAS2R14 2007/4885 |
| US-20070191479-A1 | Aniline derivatives as selective androgen receptor modulators | AR, NR3C2, NR5A1 | AR 1/4885SLC22A12 2416/4885TAS2R14 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.